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ABSTRACT - The US Food and Drug Administration (FDA) has recently suggested that the bioequivalence 
(BE) for products of drugs with narrow therapeutic indices (NTI) be assessed by the approach of reference-
scaled average BE (SABE). Subsequently, in December, 2012, the FDA issued draft guidances for the 
comparison of products of warfarin sodium and of tacrolimus. The guidances expect that 4-period studies be 
performed, that the results be evaluated by SABE, and that the analysis include also unscaled average BE as 
well as the comparison of the estimated within-subject variations (sW) of the test and reference drug products. 
This communication discusses the new guidances and suggests considerations to reduce the regulatory burden. It 
is demonstrated that SABE could be applied when the within-subject variation of the reference product is not 
higher than 21.42%. Beyond this variation, the BE limits would remain 80% to 125%, as usual. No further 
testing by unscaled average BE is needed. It is also suggested that a comparison of the within-subject variations 
of the two drug products although interesting for both NTI and other drugs, is not essential for the determination 
of BE. In addition, when the within-subject variabilities are low then their ratio depends mainly on the non-
product dependent factors. Moreover, introduction of an additional test would affect the probabilities involved in 
the primary comparison of the two means. Therefore, the test of comparing variances is not needed and replicate 
measurements of the test formulation need not be performed. Alternative considerations and approaches, 
including the use of partial AUC’s, are suggested for the determination of BE for NTI drugs.  
 
This article is open to POST-PUBLICATION REVIEW.  Registered readers (see "For Readers") may 
comment by clicking on ABSTRACT on the issue's contents page. 
  
 
 
INTRODUCTION 
 
The Food and Drug Administration (FDA) 
published recently a new draft guidance on the 
determination of bioequivalence of warfarin sodium 
formulations (1). The new guidance has a number 
of new and even novel features. This is interesting 
to potential sponsors of bioequivalence (BE) studies 
and to those interested in regulatory sciences. 
Subsequently, another draft guidance was issued on 
the bioequivalence of tacrolimus formulations (2). 
It referred for the methodology to be applied to the 
draft guidance on warfarin (1). 
 The new features include the application of 
the approach of scaled average bioequivalence 
(SABE) to the bioequivalence of warfarin or 
tacrolimus products and, by implication, to 
preparations of drugs with narrow therapeutic 
indices (NTI) (3). The new warfarin draft guidance 
presents, for the first time, also a (disaggregated) 
criterion for the comparison of within-subject 
variations. These features will be described later in 
greater detail. 
 There is no strict definition of what is an NTI 
(or critical-dose) drug.  A general definition is, as 
Yu noted, that with NTI drugs “small differences in 
dose or blood concentration may lead to serious 
therapeutic failures and/or adverse drug reactions” 
(4). Warfarin is an NTI drug for which several 
investigations compared the effects of different 
products. Reviews of studies noted that brand-name 
and most generic products had closely similar 
bioavailabilities and clinical outcomes (5-7).  
Nevertheless, caution  was  often  offered  in studies 
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and editorials against switching among warfarin 
products. 
 Tacrolimus is also an NTI drug (2, 8, 9). Its 
various formulations were found to be 
bioequivalent in healthy subjects (e.g., 10-13). 
However, concern was expressed about the scarcity 
of BE data in transplant patients (14). 
 The question arises if, with the new features 
of the warfarin draft guidance, the determination of 
BE for NTI drug products is implemented most 
advantageously. The purpose of this communication 
is to explore some answers to this question and to 
suggest alternative possibilities. 
 First, relevant aspects of the new warfarin 
draft guidance will be summarized. This will be 
followed by an exploration of some of its 
quantitative features. Comments and 
recommendations will be presented of alternatives 
which may have benefits of reduced regulatory 
burden and enhanced simplicity.   
 
BACKGROUND 
 
Draft Guidance on the Bioequivalence of 
Warfarin Sodium Products 
The procedures proposed in the recent warfarin 
draft guidance (1) will be briefly described together 
with relevant background information when 
necessary. 
 The draft guidance suggests that fully 
replicated 4-way crossover in vivo studies be 
performed on healthy males and nonpregnant 
females chosen from the general population. The 
studies are to be undertaken under both fasting and 
fed conditions. Preparations of 10 mg tablets of 
warfarin sodium are to be administered orally. 
 The method of reference-scaled average 
bioequivalence (SABE) should be applied for the 
statistical comparison of the relevant 
pharmacokinetic parameters. The approach has 
been proposed to evaluate the BE of highly-variable 
drugs and drug products (15). FDA has adopted and 
implemented it (16, 17). The procedure modifies 
the usual requirement for the determination of BE. 
Typically, the means (µ) of a test (T) and a 
reference (R] formulation are compared following 
the logarithmic transformation of the data. It is 
expected for (unscaled) average BE that the two 
90% confidence interval around the difference 
between the two logarithmic means be within the 
preset bioequivalence limits (BEL): 
 
 -BEL  ≤  µT - µR  ≤  BEL  [1] 
 
BEL is usually set at the value of ln(1.25). 
Consequently, the usual regulatory requirement is, 
by applying the approach of (unscaled) average BE, 
that the 90% confidence interval around the ratio of 
the geometric means between the two drug products 
be within the range of 0.80 to 1.25. 
 In the approach of scaled average BE, the 
difference between the logarithmic means is 
standardized by the within-subject standard 
deviation of the reference formulation (σWR):  
 
 -θA  ≤  (µT - µR)/σWR  ≤  θA [2] 
 
The bioequivalence limits for the scaled, SABE 
procedure (θA) and the unscaled average BE (BEL) 
are related by: 
 
 θA  =  ln(BEL)/σW0  [3] 
 
Here σW0 is a constant the value of which is set by 
the regulatory authorities. 
 The draft guidance on the BE of warfarin 
products recommends BEL = 1/0.9 = 1.11111 and 
σW0 = 0.10 (1).  Consequently, the scaled average 
BE limit is  θA = 1.054. 
 
Steps of Statistical Analysis Recommended by 
the Draft Guidance 
The steps presented by the draft guidance will be 
briefly summarized. 
 Step 1.  Calculate the estimated within-
subject standard deviation of the reference product 
(sWR), from the results of the completed study, by 
the usual procedure applied to a (balanced) replicate 
design.  
 Step 2.  Apply the procedure of reference-
scaled average BE (SABE) to each pharmacokinetic 
parameter.  Evaluate the upper 95% confidence 
bound to the linearized, squared and rearranged 
form of SABE: 
 
 (µT - µR)2  -  θA2 * σWR2  ≤  0 [4] 
 
By inserting estimated values of the means and the 
variance, and their distributions, the approximate 
confidence bound can be calculated (18, 19) 
following the approach of Howe (20). 
 Step 3.  By using unscaled average BE, 
evaluate, for each pharmacokinetic parameter, the 
90% confidence interval around the ratio of 
geometric means of the two drug products. The 
90% confidence limits should be, as usual, between 
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0.8000 and 1.2500.   
 Step 4.  Evaluate the upper limit of the 90% 
confidence interval for the ratio of within-subject 
standard deviations of the two drug products. The 
ratio of the variances is characterized by an F-
distribution.  The calculated 90% upper limit should 
not be higher than 6.25, i.e., the estimated upper 
limit for the ratio of the standard deviations should 
not exceed 2.5. 
 
POSSIBLE REDUCTIONS OF THE 
REGULATORY BURDEN 
 
Confidence Limits for Unscaled Average BE 
It will be useful to consider scaled average BE in a 
corresponding but different form.  Multiplying the 
defining equation [2] by σWR yields: 
 
- θA* σWR  ≤  µT - µR  ≤  θA* σWR  [5] 
 
The expression characterizes unscaled average 
bioequivalence, as in Eq. 1, but with expanding 
limits (ABEL) (19, 21). The limits are proportional 
to the within-subject standard deviation (σWR).  
 The approach of ABEL has the advantage 
over the procedure of SABE that it can be easily 
assessed by Schuirmann’s two one-sided tests 
method (22). The expanding limits can be 
calculated by using the values for BEL = 1.11111 
and σW0 = 0.10 suggested by the draft guidance for 
warfarin. The limits are illustrated against 
increasing within-subject variation in Figure 1. (The 
diagram displays the variation in terms of the intra-
subject coefficient of variation.) Similar figures 
were shown at a meeting of the FDA Advisory 
Committee but without the interpretation given here 
(23-26). 
 As expected, the implied BE limits are seen 
to expand with increasing variation. However, it is 
not desirable that the BE limits be wider than the 
customary range of 0.80 to 1.25. This is the intent 
of Step 3 of the draft guidance. Thus, above a 
certain variation, the widening of the BE limits 
should stop. This is also illustrated in Figure 1. The 
figure demonstrates that the widening stops at a 
coefficient of variation of 21.42% beyond which the 
BE limits remain constant. 
 It can thus be concluded that the approaches 
of SABE and ABEL may be applied if, and only if, 
the within-subject variation of the reference product 
does not exceed 21.42%. Therefore it is sufficient to 
estimate the value of σWR and see if it is below or 
above 0.2118 (corresponding to CV = 21.42%). No  
 
Figure 1.  Implied bioequivalence limits for the 
comparison of NTI drug products.  With increasing 
within-subject variation of the reference product, the BE 
limits widen until CV = 21.42%.  The limits remain 
constant at 0.80 and 1.25 at higher variations. 
 
 
additional test is needed to demonstrate the 
separation of regions where either scaled or 
unscaled average BE should be evaluated. 
Consequently, Step 3 of suggested testing 
procedure is superfluous and unnecessary. 
 
Determination of the Within-Subject Variation 
of Both Drug Products 
The warfarin draft guidance suggests that the 
within-subject variations of not only the reference 
formulation but also of the test product be estimated 
(σWR and σWT, respectively). This can be 
accomplished, as the draft guidance recommends 
(1), if both formulations are measured twice in each 
subject. 
 As noted earlier, the draft guidance expects 
that the two variations be compared, in Step 4, by 
an F-test.  This is a new requirement in the area of 
evaluating BE studies. It is not clear that it is 
needed any more for NTI drugs than for drugs not 
in this category.  
 The within-subject variations of drugs and 
drug products are interesting. These data are always 
“nice to know”. However, it not clear that they are 
essential in determinations of BE for either NTI or 
other drugs. Similarly, placing a cap on the 
deviation between the variations observed for the 
two formulations is potentially attractive. However, 
it is not more important for NTI drugs, notably for 
warfarin and tacrolimus, than for other drugs. 
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 Therefore it is suggested that it is not 
necessary to replicate measurements of the test 
product within individuals. Also, Step 4 suggested 
in the warfarin draft guidance (1) is not needed. 
 Two additional comments are offered in 
regard to the comparison of variances in BE studies. 
First, the proposal was offered and discussed 
extensively earlier in connection with the evaluation 
of individual and population bioequivalence (27, 
28). At that time, aggregated regulatory criteria 
were considered. The warfarin draft guidance 
presents a disaggregated regulatory expectation. 
 Secondly, introduction of a second regulatory 
criterion, that for the comparison of variances, 
would affect and alter the features for the errors of 
the principal criterion, that for the comparison of 
the means. This aspect is of concern and should be 
further investigated.  
 
DISCUSSION  
 
Are Separate Estimates of Within-Subject 
Variations Needed for NTI Drug Products? 
It is questionable that the comparison of σWR and 
σWT is meaningful if they are low which is typical 
for NTI drugs. The within-subject variation is a net 
effect of errors from many different sources. When 
CVWR is low (say, less than 20%) then error sources 
include, first, the bioanalytical error. The 
bioanalytical guidelines (29, 30) require only that 
the precision determined at each concentration level 
should not exceed 15% except at the lower limit of 
quantitation (LLOQ) at which it should not be 
higher than 20%. Thus, the bioanalytical error 
component can be quite substantial, particularly for 
Cmax. Other potential and often neglected error 
sources are the differences between the actual and 
nominal contents of active ingredients and the 
within-batch variations.  
 Furthermore, warfarin is a BCS Class 1 drug 
(31). Tablets of warfarin have uncomplicated 
technology and its bioavailability is nearly 
complete. If warfarin were not an NTI drug then its 
bioavailability could be decided based on in-vitro 
tests. Therefore, it is questionable that screening for 
product-related specific differences between σWR 
and σWT is a reasonable approach for warfarin. 
Thus, separate estimates of σWR and σWT may not be 
needed for low-variability BCS Class 1drugs. 
 
Consistency between Regulatory Requirements  
There are many regulatory requirements which 
should be met by generic products to get approval. 
For instance, the United States Pharmacopeia (USP) 
specifies for content variability that 10 tablets from 
any batch must contain 85% to 115% of the labelled 
strength, with a standard deviation of less than 6%. 
This requirement is more liberal than the proposed 
bioequivalence criterion. Thus, a situation could 
arise that allowed the tablet-to-tablet difference of 
the reference product to be potentially larger than 
the allowed difference between the test and 
reference formulations. This is counterintuitive and 
forces to rethink the consequences of changing only 
one of the regulatory rules. Stability requirements 
could be another, similar issue. Thus, 
bioequivalence expectations should be set in 
harmony with other quality requirements in order to 
avoid inconsistencies in the regulatory framework. 
For warfarin generics, producers often apply stricter 
content variability standards than the originator 
(32). It is not clear that such stricter criteria are 
general and applicable in other cases. 
 
Alternative Approaches 
It is still debatable whether a specific regulation is 
needed for the bioequivalence of NTI drugs. There 
are only sporadic clinical reports about negative 
consequences of switching. Hard evidence in the 
form of randomized clinical trials is not available 
and not even expected to be available in the near 
future. But using data of a small bioequivalence 
trial with carbamazepine (CBZ), which is an NTI 
drug, it was demonstrated that the concern is not 
imaginary. Two have been offered which could 
support the cautionary approach to generic 
switching with this drug (33, 34). First, it has been 
reported that the relative risk of neurological 
adverse effects increases by as much as 50% due to 
switching between two CBZ formulations which 
were otherwise bioequivalent. In that case, Cmax was 
not a sensitive metric which would be able to 
capture clinically important differences. As a 
remedy, the use of partial AUC was suggested for 
assessing the bioequivalence of CBZ tablets (33).  
 A second explanation is based on the 
observation that the assumption that bioequivalence 
results obtained in a healthy population in single-
dose studies can be extrapolated to the target patient 
population at the steady state, is not always true 
(34). CBZ is a strong enzyme inducer (35) and the 
Cmax and Cmin concentrations depend on the 
clearance. A small difference between Cmax values 
in a healthy population can be significantly higher 
in the target group. Two formulations which are 
bioequivalent in a single-dose study with healthy 
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volunteers may not be bioequivalent at steady state 
in patients.   
 Neither of these problems, the inadequate 
metric and/or inadequate study population, is 
addressed directly by the proposed new regulation. 
Instead, it focuses on the presumed problem of 
variation difference between the test and reference 
formulations. It remains to be demonstrated that this 
is a real clinical problem or just an interesting 
statistical concept. 
 
CONCLUDING REMARKS 
 
The procedure in the new draft guidance of FDA on 
the BE of warfarin sodium products is remarkably 
innovative (1). Most importantly, it introduces the 
application of the scaled average BE procedure to 
the BE of formulations of a drug having a narrow 
therapeutic index. Another example is the new draft 
guidance on the comparison of tacrolimus 
formulations (2). 
 The present communication recognizes the 
main feature of the new draft guidances, the 
introduction of the procedure of scaled average BE 
for certain NTI drugs. At the same time, 
suggestions are offered in order to reduce the 
regulatory burden. 
 The first recommendation is simple and 
straightforward. It is not necessary to calculate the 
90% confidence limits with unscaled average BE 
(Step 3 in the draft guidance) in order to ascertain if 
the limits obtained with SABE would or would not 
exceed the 0.80 to 1.25 range. If the estimated 
within-subject variation of the reference product 
does not exceed 21.42% then, automatically, the 
unscaled average BE limits are not penetrated. 
 The second suggestion observes that FDA 
introduces a new, additional regulatory criterion 
comparing, by an F-test, the within-subject 
variances of the two formulations and placing a cap 
on their ratio. This information is interesting but not 
more important and essential for comparing 
formulations of NTI drugs than of other drugs. It is 
further noted that the additional regulatory criterion 
modifies the statistical features of the primary 
criterion that of comparing the means. Therefore it 
is suggested that Step 4 described in the warfarin 
draft guidance (1) is not needed. Also, it is not 
necessary to obtain replicate measurements of the 
test formulation within individuals. 
 The suggestions and remarks in the present 
communication arise from and immediately apply 
to the recently issued FDA draft guidances on the 
BE of warfarin sodium and tacrolimus products (1, 
2). However, the agency indicated that it intends to 
apply the approach of scaled average BE, more 
generally, to products of drugs having narrow 
therapeutic indices (3, 25, 36). The Advisory 
Committee on Pharmaceutical Science and Clinical 
Pharmacology supported this intention (37). Thus, 
our suggestions and remarks may have wider 
relevance.  
 It is often assumed that NTI drugs have small 
within-subject variations (3, 38) and that the 
assessment of BE for their products should involve 
narrower than the usual BE limits. The assumption 
of small intrasubject variation is not always valid. 
For example, for dalbigatran, in a replicate-design 
study, the geometric CVs of the two formulations 
for AUC were 62.2% and 44.3%, and for Cmax 
64.7% and 45.5% (39).   
 As a consequence of this assumption, 
regulatory guidances call for narrower 
bioequivalence limits by, for instance, EMA, Health 
Canada and, now, FDA (2, 3, 8, 40). However, 
questions can be raised about this regulatory 
expectation. For instance, alternative metrics such 
as partial AUC, could provide a more effective 
approach for dealing with the issue of BE for NTI 
products (33). 
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